| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to heterocyclic compound of formula or to its pharmaceutically acceptable salt, where Alk represents linear C 1-6 alkylene group, branched C 1-6 alkylene group or C 1-6 alkylene group, which has ring structure, where part of carbon atoms, constituting ring structure can be optionally substituted with oxygen atom, in ring X, X 1 represents N or CR X1 , X 2 represents N or CR X2 , X 3 represents CR X3 , X 4 represents N or CR X4 , where R X1 , R X2 , R X3 and R X4 each independently represents hydrogen atom; linear or branched C 1-6 alkyl group; linear or branched C 1-6 alcoxygroup; or halogen atom, in ring Y, Y 1 represents CR Y1 , Y 2 represents N or CR Y2 , Y 3 represents N or CR Y3 , Y 4 represents N or CR Y4 , R Y1 , R Y2 , R Y3 and R Y4 each independently represents hydrogen atom; linear or branched C 1-6 alkyl group, which can be substituted with halogen atom(s); C 3-7 alkyl group, which has ring structure; linear or branched C 1-6 alkoxygroup; halogen atom or cyanogroup, in ring Z, R Z represents linear or branched C 1-6 alkyl group, which can be substituted with halogen atom(s), or C 3-7 alkyl group, which has ring structure, which can be substituted with halogen atom(s). Invention also relates to particular compounds, DGAT1 inhibitor based on formula (I) compound, application of formula (I) compound, method of prevention or treatment of diseases, mediated by DGAT1 inhibition. n EFFECT: obtained are novel compounds, possessing useful biological activity. n 19 cl, 19 tbl, 149 ex |